Faylene Lunn

Faylene Lunn

Partner, Intellectual Property

Contact Information


tel: 613.787.1025



Bar Admission

Ontario, 2012


  • Dalhousie University, J.D.
  • Dalhousie University, Ph.D.
  • Mount Allison University, B.Sc. (Hons.)



Faylene practises intellectual property law with a focus on patent litigation, including proceedings under the Patented Medicine (Notice of Compliance) Regulations. Faylene has been involved in assisting clients on protecting and enforcing their patent portfolios in multiple jurisdictions. She also regularly prepares infringement, validity and freedom-to-operate opinions, particularly in respect of pharmaceutical patents.

A trained scientist with a doctorate in biochemistry and molecular biology from Dalhousie University, Faylene has had her scientific work in enzymology, organic chemistry, molecular biology and microbiology published in peer-reviewed journals and has presented at national and international chemistry conferences.


    Faylene has been involved in:

    • Representing Teva Canada in the Federal Court’s strike of judicial review by Novo Nordisk Canada Inc.
    • Representing major international pharmaceutical companies in applications under the Patented Medicines (Notice of Compliance) Regulations
    • Representing a health and wellness company in a patent infringement action 

  • Managing Intellectual Property: Rising Star
  • The Doug Hogue Award for exceptional dedication and achievement in research and intradepartmental student activity
  • World Intellectual Property Review (WIPR): Global Leader (2023)
  • Walter C. Sumner Fellowship
  • The Nova Scotia Health Research Foundation Ph. D. Studentship

  • Chair, National Intellectual Property Section of the Canadian Bar Association (2022-2023)
  • Intellectual Property Institute of Canada
  • Ontario Bar Association

  • Bloom G, Sookman B, Klee M, Fong B, Dawalibi D, Lunn F, Plamondon F. Canadian Copyright, Design, and Related Legislation and Jurisprudence: 2011. C.I.P. Rev. 2012; 28(1): 3-38.
  • Lunn FA, Macleod TJ, Bearne SL. Mutational analysis of conserved glycine residues 142, 143 and 146 reveals Gly(142) is critical for tetramerization of CTP synthase from Escherichia coli. Biochem J. 2008; 412(1):113-21.
  • Lunn FA, MacDonnell JE, Bearne SL. Structural requirements for the activation of Escherichia coli CTP synthase by the allosteric effector GTP are stringent, but requirements for inhibition are lax. J Biol Chem. 2008; 283(4):2010-20.